PT3555105T - Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes - Google Patents

Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes

Info

Publication number
PT3555105T
PT3555105T PT178228821T PT17822882T PT3555105T PT 3555105 T PT3555105 T PT 3555105T PT 178228821 T PT178228821 T PT 178228821T PT 17822882 T PT17822882 T PT 17822882T PT 3555105 T PT3555105 T PT 3555105T
Authority
PT
Portugal
Prior art keywords
phenylethylamino
pyrimido
oxazin
compounds
mutant idh1
Prior art date
Application number
PT178228821T
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT3555105T publication Critical patent/PT3555105T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT178228821T 2016-12-16 2017-12-08 Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes PT3555105T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
PT3555105T true PT3555105T (pt) 2020-12-21

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178228821T PT3555105T (pt) 2016-12-16 2017-12-08 Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes

Country Status (37)

Country Link
US (3) US11001596B2 (pt)
EP (2) EP3763717B1 (pt)
JP (1) JP6793836B2 (pt)
KR (1) KR102276022B1 (pt)
CN (2) CN115109075B (pt)
AU (2) AU2017378060B2 (pt)
CA (1) CA3045303C (pt)
CL (1) CL2019001551A1 (pt)
CO (1) CO2019005287A2 (pt)
CR (1) CR20190252A (pt)
CY (1) CY1123577T1 (pt)
DK (1) DK3555105T3 (pt)
DO (1) DOP2019000163A (pt)
EA (1) EA036112B1 (pt)
EC (1) ECSP19042682A (pt)
ES (2) ES2835281T3 (pt)
HR (1) HRP20201882T1 (pt)
HU (1) HUE052067T2 (pt)
IL (1) IL267236B (pt)
JO (1) JOP20190142B1 (pt)
LT (1) LT3555105T (pt)
MA (2) MA47399B1 (pt)
MD (1) MD3555105T2 (pt)
MX (1) MX385562B (pt)
MY (1) MY197313A (pt)
NZ (1) NZ754115A (pt)
PE (1) PE20190977A1 (pt)
PH (1) PH12019501328B1 (pt)
PL (1) PL3555105T3 (pt)
PT (1) PT3555105T (pt)
RS (1) RS61108B1 (pt)
SA (1) SA519401897B1 (pt)
SI (1) SI3555105T1 (pt)
TN (1) TN2019000158A1 (pt)
UA (1) UA123640C2 (pt)
WO (1) WO2018111707A1 (pt)
ZA (1) ZA201903125B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102209667B1 (ko) 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317321B2 (en) 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
EP3201185B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
JOP20190090B1 (ar) 2016-10-24 2023-03-28 Astrazeneca Ab مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PH12019501328B1 (en) * 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
EP3689873B1 (en) 2017-01-30 2022-09-14 Astrazeneca AB Estrogen receptor modulators
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11497743B2 (en) 2018-05-16 2022-11-15 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11738018B2 (en) 2018-05-16 2023-08-29 FORMA Therapeuetics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
ES3033669T3 (en) 2019-11-08 2025-08-06 Nerviano Medical Sciences Srl Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
AU2021241470B2 (en) * 2020-03-23 2023-12-14 Board Of Regents, The University Of Texas System Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor
ES2981250T3 (es) * 2020-03-23 2024-10-08 Lilly Co Eli Terapia combinada con un inhibidor de IDH mutante
IL296094A (en) * 2020-03-23 2022-11-01 Lilly Co Eli Method for treating idh1 inhibitor-resistant subjects
JP7712955B2 (ja) 2020-04-24 2025-07-24 アストラゼネカ・アクチエボラーグ 癌の治療のための投薬レジメン
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
CN115768775B (zh) * 2020-06-28 2024-10-25 微境生物医药科技(上海)有限公司 Idh突变体抑制剂及其用途
JP2023534991A (ja) * 2020-07-20 2023-08-15 イーライ リリー アンド カンパニー 変異型ｉｄｈ１阻害剤、デオキシアデノシン類似体、及び白金剤を用いた併用療法
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
CN117460514A (zh) * 2021-06-09 2024-01-26 伊莱利利公司 用于治疗idh抑制剂耐药的对象的方法
US20240208978A1 (en) * 2021-06-15 2024-06-27 Wigen Biomedicine Technology (shanghai) Co., Ltd. Idh mutant inhibitor and use thereof
CA3224704A1 (en) 2021-08-13 2023-02-16 David Andrew Coates Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2-enoylpiper azin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012313888B2 (en) * 2011-09-27 2016-03-31 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
BR112015022483A2 (pt) * 2013-03-14 2017-07-18 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
WO2016171755A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171715A1 (en) * 2015-04-24 2016-10-27 Halliburton Energy Services, Inc. Methods of fabricating ceramic or intermetallic parts
JP6473270B2 (ja) * 2015-07-27 2019-02-20 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用
ES2814290T3 (es) * 2016-06-06 2021-03-26 Lilly Co Eli Inhibidores de IDH1 mutante
PH12019501328B1 (en) * 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors

Also Published As

Publication number Publication date
US11629156B2 (en) 2023-04-18
EA036112B1 (ru) 2020-09-29
CL2019001551A1 (es) 2019-10-25
KR102276022B1 (ko) 2021-07-13
MD3555105T2 (ro) 2021-01-31
AU2020260493B2 (en) 2021-09-09
JP2020502157A (ja) 2020-01-23
RS61108B1 (sr) 2020-12-31
JOP20190142B1 (ar) 2023-03-28
PL3555105T3 (pl) 2021-05-17
CN110072867A (zh) 2019-07-30
WO2018111707A1 (en) 2018-06-21
US11649247B2 (en) 2023-05-16
CR20190252A (es) 2019-08-26
ES2835281T3 (es) 2021-06-22
CN115109075A (zh) 2022-09-27
CN110072867B (zh) 2022-07-08
IL267236A (en) 2019-08-29
SA519401897B1 (ar) 2022-07-28
ES2941631T3 (es) 2023-05-24
MY197313A (en) 2023-06-13
EP3763717A1 (en) 2021-01-13
AU2020260493A1 (en) 2020-11-26
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
SI3555105T1 (sl) 2020-12-31
UA123640C2 (uk) 2021-05-05
DK3555105T3 (da) 2020-11-09
CY1123577T1 (el) 2022-03-24
MA47399B1 (fr) 2021-02-26
PE20190977A1 (es) 2019-07-09
BR112019009648A2 (pt) 2019-09-10
MX385562B (es) 2025-03-18
TN2019000158A1 (en) 2020-10-05
MX2019006830A (es) 2019-08-22
KR20190077539A (ko) 2019-07-03
IL267236B (en) 2020-08-31
MA53881A (fr) 2022-04-27
AU2017378060A1 (en) 2019-05-30
US20200079791A1 (en) 2020-03-12
HUE052067T2 (hu) 2021-04-28
EP3555105A1 (en) 2019-10-23
CN115109075B (zh) 2024-09-20
EP3555105B1 (en) 2020-10-28
CO2019005287A2 (es) 2019-05-31
CA3045303C (en) 2022-05-17
DOP2019000163A (es) 2019-07-15
LT3555105T (lt) 2021-01-11
ZA201903125B (en) 2024-08-28
CA3045303A1 (en) 2018-06-21
PH12019501328B1 (en) 2023-05-12
HRP20201882T1 (hr) 2021-01-22
EA201991161A1 (ru) 2019-11-29
JP6793836B2 (ja) 2020-12-02
PH12019501328A1 (en) 2020-02-24
ECSP19042682A (es) 2019-06-30
JOP20190142A1 (ar) 2019-06-13
EP3763717B1 (en) 2023-03-08
US20210230185A1 (en) 2021-07-29
AU2017378060B2 (en) 2020-09-03
MA47399A (fr) 2019-10-23
NZ754115A (en) 2021-07-30

Similar Documents

Publication Publication Date Title
IL267236B (en) Derivatives of 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one as 1idh and 2idh mutant inhibitors
IL279363A (en) PCSK9 antagonist compounds
ZA201802181B (en) 2¿phenyl¿3,4¿dihydropyrrolo[2,1 ¿f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
EP3303382A4 (en) Compositions and methods for treating patients with rtk mutant cells
HK1251624A1 (zh) Kras表达的调节剂
WO2017019429A8 (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant idh1 inhibitors
HK1217410A1 (zh) Erk抑制劑及其用途
EP2968311A4 (en) OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS
EP2665713A1 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
EP2670738A2 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
EP3262174A4 (en) Compounds and methods for increasing antisense activity
EP3240768A4 (en) Nitrification inhibitor compositions and methods for preparing the same
IL278701A (en) Heterofused pyridones and their use as IDH inhibitors
EP3356357A4 (en) COMPOSITIONS AND METHODS OF INHIBITING BETA LACTAMASE
WO2014160628A3 (en) Articles and methods for preventing and treating dermatologic adverse events
EP3192513A4 (en) 7-fluoro-8-chloro-5 -dibenzo[b,e][1,4]diazepine derivatives and use thereof
HK40047118A (en) Pcsk9 antagonist compounds
HK40011990A (en) Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
HK40004368A (en) Compounds and compositions for treating conditions associated with nlrp activity
TH1501007226A (th) สารประกอบ 6,7-ไดไฮโดรไพราโซโล[1,5-a]ไพราซีน-4(5H)-โอน และการใช้ของ สิ่งนั้นในฐานะเป็นสารยับยั้งแอลโลสเตอริกของ mGluR2 รีเซ็ปเตอร์
HK40017066A (en) Methods and compositions for preventing or minimizing epithelial-mesenchymal transition
HK1260536A1 (en) Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
HK1262447A1 (en) Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof
AU2016901442A0 (en) Methods and compositions for preventing and/or treating cataracts
AU2013900546A0 (en) Accessory for furniture piece and furniture piece having the accessory